These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 22688528)
1. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Idris I; Warren G; Donnelly R Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528 [TBL] [Abstract][Full Text] [Related]
2. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009 [TBL] [Abstract][Full Text] [Related]
3. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002 [TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894 [TBL] [Abstract][Full Text] [Related]
5. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Sun GE; Wells BJ; Yip K; Zimmerman R; Raghavan D; Kattan MW; Kashyap SR Diabetes Obes Metab; 2014 Mar; 16(3):276-83. PubMed ID: 24199848 [TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones and fractures in men and women. Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303 [TBL] [Abstract][Full Text] [Related]
7. Use of thiazolidinediones and fracture risk. Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256 [TBL] [Abstract][Full Text] [Related]
8. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Ambrosius WT; Danis RP; Goff DC; Greven CM; Gerstein HC; Cohen RM; Riddle MC; Miller ME; Buse JB; Bonds DE; Peterson KA; Rosenberg YD; Perdue LH; Esser BA; Seaquist LA; Felicetta JV; Chew EY; Arch Ophthalmol; 2010 Mar; 128(3):312-8. PubMed ID: 20212201 [TBL] [Abstract][Full Text] [Related]
9. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Hartung DM; Touchette DR; Bultemeier NC; Haxby DG Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176 [TBL] [Abstract][Full Text] [Related]
10. Distal upper and lower limb fractures associated with thiazolidinedione use. Jones SG; Momin SR; Good MW; Shea TK; Patric K Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952 [TBL] [Abstract][Full Text] [Related]
11. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780 [TBL] [Abstract][Full Text] [Related]
12. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Gerrits CM; Bhattacharya M; Manthena S; Baran R; Perez A; Kupfer S Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425 [TBL] [Abstract][Full Text] [Related]
13. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800 [TBL] [Abstract][Full Text] [Related]
14. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Pinelli NR; Cha R; Brown MB; Jaber LA Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626 [TBL] [Abstract][Full Text] [Related]
15. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Stockl KM; Le L; Zhang S; Harada AS Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802 [TBL] [Abstract][Full Text] [Related]
16. Glitazone use associated with diabetic macular edema. Fong DS; Contreras R Am J Ophthalmol; 2009 Apr; 147(4):583-586.e1. PubMed ID: 19181303 [TBL] [Abstract][Full Text] [Related]
17. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis. Koro CE; Sowell MO; Stender M; Qizilbash N Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791 [TBL] [Abstract][Full Text] [Related]
18. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Durbin RJ Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752 [TBL] [Abstract][Full Text] [Related]
19. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708 [TBL] [Abstract][Full Text] [Related]
20. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]